Juliya Fisher1, Nathalie Zeitouni2, Weijia Fan3, Faramarz H Samie4. 1. Department of Dermatology, Columbia University Irving Medical Center, New York, New York. 2. Department of Dermatology, University of Arizona College of Medicine, Phoenix, Arizona. 3. Department of Biostatistics, Columbia University Irving Medical Center, New York, New York. 4. Department of Dermatology, Columbia University Irving Medical Center, New York, New York. Electronic address: fs2614@cumc.columbia.edu.
Abstract
BACKGROUND: The use of immunotherapies in the treatment of metastatic cancers has significantly advanced oncology. However, due to safety concerns, solid organ transplant recipients (SOTRs) are routinely excluded from immunotherapy trials; thus, there is limited data for these agents in this population. METHODS: A systematic review was performed to evaluate the safety and efficacy of immunotherapies in SOTRs with metastatic cancers. Fisher's exact test and Kruskal-Wallis test were used for analysis. RESULTS: In total, 37% of patients experienced organ rejection, and 14% died as a result of graft rejection. Nivolumab was associated with the highest rejection rate (52.2%), followed by pembrolizumab (26.7%) and ipilimumab (25%; P = .1774). The highest rejection rate was seen in patients with kidney transplants (40.1%), then liver (35%) and heart (20%) transplants (P = .775), and 64% of patients succumbed to the progression of malignancy. For all cases, rates of progression or death secondary to disease were highest for ipilimumab (75%), followed by nivolumab (43%) and pembrolizumab (40%; P = .1892). The overall response rate was highest for pembrolizumab (40%), followed by nivolumab (30%) and ipilimumab (25%; P = .7929). LIMITATIONS: The small sample size. CONCLUSION: Physicians must be cautious when administering immunotherapy to SOTRs. However, rejection is not the most common cause for death in this population.
BACKGROUND: The use of immunotherapies in the treatment of metastatic cancers has significantly advanced oncology. However, due to safety concerns, solid organ transplant recipients (SOTRs) are routinely excluded from immunotherapy trials; thus, there is limited data for these agents in this population. METHODS: A systematic review was performed to evaluate the safety and efficacy of immunotherapies in SOTRs with metastatic cancers. Fisher's exact test and Kruskal-Wallis test were used for analysis. RESULTS: In total, 37% of patients experienced organ rejection, and 14% died as a result of graft rejection. Nivolumab was associated with the highest rejection rate (52.2%), followed by pembrolizumab (26.7%) and ipilimumab (25%; P = .1774). The highest rejection rate was seen in patients with kidney transplants (40.1%), then liver (35%) and heart (20%) transplants (P = .775), and 64% of patients succumbed to the progression of malignancy. For all cases, rates of progression or death secondary to disease were highest for ipilimumab (75%), followed by nivolumab (43%) and pembrolizumab (40%; P = .1892). The overall response rate was highest for pembrolizumab (40%), followed by nivolumab (30%) and ipilimumab (25%; P = .7929). LIMITATIONS: The small sample size. CONCLUSION: Physicians must be cautious when administering immunotherapy to SOTRs. However, rejection is not the most common cause for death in this population.
Authors: Diego L Kaen; Nicolas Minatta; Alessandro Russo; Umberto Malapelle; Diego de Miguel-Pérez; Christian Rolfo Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622
Authors: Benjamin C Park; Seungyeon Jung; Steven T Chen; Anna K Dewan; Douglas B Johnson Journal: Am J Clin Dermatol Date: 2022-06-16 Impact factor: 6.233
Authors: Itunu Owoyemi; Lisa E Vaughan; Collin M Costello; Charat Thongprayoon; Svetomir N Markovic; Joerg Herrmann; Clark C Otley; Timucin Taner; Aaron R Mangold; Nelson Leung; Sandra M Herrmann; Aleksandra Kukla Journal: Cancer Date: 2020-08-12 Impact factor: 6.860